Skip to content

Comparison of hypotensive effect between remimazolam and propofol in anesthesia of elderly

Comparison of hypotensive effect induced by remimazolam and propofol during total intravenous anesthesia in the elderly - a randomized control trial.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0006719
Enrollment
132
Registered
2021-11-08
Start date
2021-11-08
Completion date
Unknown
Last updated
2023-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Both group undergoes total intravenous anesthesia. Intervention group uses remimazolam for hypnotic drug, and control group uses propofol. For intraoperative analgesia, remifentanil is administ

Sponsors

Yonsei University, Wonju Severance Christian Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - patients undergoing elective surgery with general anesthesia - laparoscopic cholecystectomy or transurethral bladder resection

Exclusion criteria

Exclusion criteria: - ASA PS classification > III - ambulatory surgery - unable to measure blood pressure at the upper arm non-invasively, or at radial artery invasively - chronic alcoholics - BMI = 30 - Hypersensitivity to remimazolam, propofol, remifentanil, ephedrine, rocuronium, sugammadex - Child-Turcotte-Pugh Class C - acute narrow angle glaucoma - mild cognitive disorder or more severe cognitive disorder - can not understand the informed consent form or lacks decision-making capacity

Design outcomes

Primary

MeasureTime frame
Incidence of hypotension

Secondary

MeasureTime frame
bradycardia and tachycardia;Delirium;unexpected admission to the ICU;mortality

Countries

Korea, Republic of

Contacts

Public ContactSeung Woo Song

Yonsei University Wonju College of Medicine

googlfong@gmail.com+82-33-741-1536

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026